Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, L Dozza, Ronnie van der Holt, S Zweegman, S Oliva, Vincent van der Velden, E Zamagni, GA Palumbo, F Patriarca, V Montefusco, M Galli, V Maisnar, B Gamberi, M Hansson, A BelottiL Pour, P Ypma, M Grasso, A Croockewit, S Ballanti, M Offidani, ID Vincelli, R Zambello, AM Liberati, NF Andersen, A. Broijl, R Troia, A Pascarella, G Benevolo, MD Levin, G Bos, H Ludwig, S Aquino, AM Morelli, KL Wu, R Boersma, R Hajek, M Durian, Pavd von dem Borne, T Caravita di Toritto, T Zander, G Specchia, A Waage, P Gimsing, UH Mellqvist, M van Marwijk Kooy, M Minnema, C Mandigers, AM Cafro, A Palmas, S Carvalho, A Spencer, M Boccadoro, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

134 Citations (Scopus)
Original languageEnglish
Pages (from-to)E456-E468
JournalThe Lancet Haematology
Volume7
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Cite this